159 related articles for article (PubMed ID: 38664644)
21. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
22. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
[TBL] [Abstract][Full Text] [Related]
23. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
[TBL] [Abstract][Full Text] [Related]
25. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
26. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Yang X; Zhang S; He C; Xue P; Zhang L; He Z; Zang L; Feng B; Sun J; Zheng M
Mol Cancer; 2020 Feb; 19(1):46. PubMed ID: 32111213
[TBL] [Abstract][Full Text] [Related]
27. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
28. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway.
Qiao K; Liu Y; Xu Z; Zhang H; Zhang H; Zhang C; Chang Z; Lu X; Li Z; Luo C; Liu Y; Yang C; Sun T
Angiogenesis; 2021 Feb; 24(1):83-96. PubMed ID: 32920668
[TBL] [Abstract][Full Text] [Related]
29. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of anticancer effects of Juniperus communis extract on hepatocellular carcinoma cells in vitro and in vivo.
Huang NC; Huang RL; Huang XF; Chang KF; Lee CJ; Hsiao CY; Lee SC; Tsai NM
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34151367
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.
Fan Z; Yang G; Zhang W; Liu Q; Liu G; Liu P; Xu L; Wang J; Yan Z; Han H; Liu R; Shu M
J Cell Mol Med; 2021 Nov; 25(21):10197-10212. PubMed ID: 34609072
[TBL] [Abstract][Full Text] [Related]
32. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.
Yi D; Wang R; Shi X; Xu L; Yilihamu Y; Sang J
Oncol Rep; 2020 May; 43(5):1375-1386. PubMed ID: 32323801
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
35. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
36. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
[TBL] [Abstract][Full Text] [Related]
37. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
Ding H; Zhang X; Su Y; Jia C; Dai C
Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
[TBL] [Abstract][Full Text] [Related]
38. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
39. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
